NASDAQ:LRMR
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. reported net income of −$165.7M in fiscal 2025. Free cash flow was −$113.3M.Summary generated from Larimar Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−132.6%
Debt / equityn/a
Free cash flow−$113.3M
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −50 | −37 | −42 | −91 | −172 |
| Net income | −51 | −35 | −37 | −81 | −166 |
| Free cash flow | −42 | −28 | −34 | −71 | −113 |
Recent filings
- 4Insider transaction report
Oct 1, 2026 - 8-KDirector or officer change
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 4Insider transaction report
Jul 8, 2026 - 8-KOther events
Jun 29, 2026 - 8-KResults of a shareholder vote
May 19, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026